150 related articles for article (PubMed ID: 16944009)
21. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results.
Taltavull TC; Chahri N; Verdura B; Gornals J; Lopez C; Casanova A; Cañas C; Figueras J; Casais LA
Transpl Int; 2005 Jul; 18(7):879-83. PubMed ID: 15948869
[TBL] [Abstract][Full Text] [Related]
22. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH
World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989
[TBL] [Abstract][Full Text] [Related]
23. Lamivudine therapy for decompensated liver cirrhosis related to hepatitis B virus infection.
Lee HC; Suh DJ
Intervirology; 2003; 46(6):388-93. PubMed ID: 14688457
[TBL] [Abstract][Full Text] [Related]
24. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
Sponseller CA; Bacon BR; Di Bisceglie AM
Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
[TBL] [Abstract][Full Text] [Related]
25. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
Cho SW; Hahm KB; Kim JH
Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
[TBL] [Abstract][Full Text] [Related]
26. The long-term effects of lamivudine treatment in patients with HBeAg-negative liver cirrhosis.
Kilic ZM; Kuran S; Akdogan M; Cicek B; Oguz D; Odemis B; Sasmaz N
Adv Ther; 2008 Mar; 25(3):190-200. PubMed ID: 18385953
[TBL] [Abstract][Full Text] [Related]
27. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis.
Lim SG; Aung MO; Mak B; Sutedja D; Lee YM; Lee GH; Fernandes M; Low HC; Lai V; Dan YY
J Clin Gastroenterol; 2011 Oct; 45(9):818-23. PubMed ID: 21921845
[TBL] [Abstract][Full Text] [Related]
29. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
30. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis.
Choe WH; Kwon SY; Kim BK; Ko SY; Yeon JE; Byun KS; Kim GH; Lee CH
Liver Int; 2008 Jul; 28(6):814-20. PubMed ID: 18312291
[TBL] [Abstract][Full Text] [Related]
31. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study.
Kim YJ; Kim BG; Jung JO; Yoon JH; Lee HS
J Gastroenterol; 2006 Mar; 41(3):240-9. PubMed ID: 16699858
[TBL] [Abstract][Full Text] [Related]
32. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P
Ann Intern Med; 1996 Nov; 125(9):705-12. PubMed ID: 8929003
[TBL] [Abstract][Full Text] [Related]
33. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
35. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
36. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Liaw YF; Lee CM; Chien RN; Yeh CT
J Viral Hepat; 2006 Apr; 13(4):250-5. PubMed ID: 16611191
[TBL] [Abstract][Full Text] [Related]
37. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
38. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.
Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF
Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494
[TBL] [Abstract][Full Text] [Related]
40. Lamivudine as initial treatment for chronic hepatitis B in the United States.
Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
